Free Trial
NASDAQ:OMCL

Omnicell (OMCL) Stock Price, News & Analysis

Omnicell logo
$30.83 -0.20 (-0.64%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$30.83 0.00 (0.00%)
As of 08/8/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Omnicell Stock (NASDAQ:OMCL)

Key Stats

Today's Range
$30.32
$31.00
50-Day Range
$26.88
$31.68
52-Week Range
$22.66
$55.74
Volume
634,920 shs
Average Volume
569,675 shs
Market Capitalization
$1.42 billion
P/E Ratio
61.66
Dividend Yield
N/A
Price Target
$45.33
Consensus Rating
Moderate Buy

Company Overview

Omnicell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

OMCL MarketRank™: 

Omnicell scored higher than 70% of companies evaluated by MarketBeat, and ranked 265th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Omnicell has only been the subject of 3 research reports in the past 90 days.

  • Read more about Omnicell's stock forecast and price target.
  • Earnings Growth

    Earnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omnicell is 61.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omnicell is 61.66, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.76.

  • Price to Earnings Growth Ratio

    Omnicell has a PEG Ratio of 9.06. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Omnicell has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.16% of the outstanding shares of Omnicell have been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 11.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Omnicell does not currently pay a dividend.

  • Dividend Growth

    Omnicell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.16% of the outstanding shares of Omnicell have been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 11.57%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Omnicell has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Omnicell this week, compared to 6 articles on an average week.
  • Search Interest

    1 people have searched for OMCL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Omnicell to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Omnicell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.52% of the stock of Omnicell is held by insiders.

  • Percentage Held by Institutions

    97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omnicell's insider trading history.
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Omnicell (NASDAQ:OMCL) Cut to Buy at Wall Street Zen
1 Small-Cap Stock for Long-Term Investors and 2 We Avoid
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Omnicell management to meet with KeyBanc
Q2 2025 Omnicell Inc Earnings Call Transcript
See More Headlines

OMCL Stock Analysis - Frequently Asked Questions

Omnicell's stock was trading at $44.52 at the beginning of 2025. Since then, OMCL shares have decreased by 30.8% and is now trading at $30.83.

Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings data on Thursday, July, 31st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.15. The business's revenue for the quarter was up 5.0% on a year-over-year basis.
Read the conference call transcript
.

Omnicell subsidiaries include these companies: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and more.

Omnicell's top institutional shareholders include Sumitomo Mitsui Trust Group Inc. (3.04%), Geode Capital Management LLC (2.55%), Connor Clark & Lunn Investment Management Ltd. (0.99%) and Bank of New York Mellon Corp (0.65%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon.
View institutional ownership trends
.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
7/31/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
CIK
926326
Employees
3,670
Year Founded
1992

Price Target and Rating

High Price Target
$64.00
Low Price Target
$34.00
Potential Upside/Downside
+47.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.50
Trailing P/E Ratio
61.66
Forward P/E Ratio
28.28
P/E Growth
9.06
Net Income
$12.53 million
Net Margins
2.01%
Pretax Margin
3.14%
Return on Equity
4.27%
Return on Assets
2.44%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.42
Quick Ratio
1.24

Sales & Book Value

Annual Sales
$1.11 billion
Price / Sales
1.27
Cash Flow
$3.04 per share
Price / Cash Flow
10.14
Book Value
$27.51 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
45,930,000
Free Float
45,664,000
Market Cap
$1.42 billion
Optionable
Optionable
Beta
0.78

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:OMCL) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners